IRIS
CERRI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 932
EU - Europa 538
AS - Asia 177
AF - Africa 6
OC - Oceania 3
SA - Sud America 1
Totale 1.657
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 925
IE - Irlanda 264
CN - Cina 162
FI - Finlandia 72
IT - Italia 54
DE - Germania 52
UA - Ucraina 36
CZ - Repubblica Ceca 16
GB - Regno Unito 14
SE - Svezia 13
FR - Francia 9
CA - Canada 7
BE - Belgio 5
JP - Giappone 5
MU - Mauritius 5
IN - India 4
AU - Australia 2
SG - Singapore 2
BR - Brasile 1
EG - Egitto 1
HK - Hong Kong 1
KW - Kuwait 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 1.657
Salva come PNG Salva come JPEG
Città #
Chandler 289
Dublin 264
Ashburn 99
Helsinki 53
Jacksonville 45
Princeton 45
Lawrence 44
Shanghai 34
Medford 33
Wilmington 30
Beijing 28
New York 24
Nanjing 23
Brno 16
Chicago 16
Nanchang 14
Shenyang 12
Washington 12
Changsha 11
Milan 11
Boardman 10
Hebei 10
Pavia 10
Fairfield 9
Hangzhou 8
Jiaxing 8
Tianjin 8
Norwalk 6
Brussels 5
Los Angeles 5
Rome 5
Tokyo 5
Toronto 5
Falls Church 4
Giessen 4
Piscataway 4
Woodbridge 4
Ningbo 3
Ann Arbor 2
Des Moines 2
Munich 2
Naples 2
Osio Sotto 2
Ostiglia 2
Salford 2
Seattle 2
Singapore 2
Southend 2
Treviso 2
Verona 2
Almere Stad 1
Atlanta 1
Auckland 1
Berlin 1
Borås 1
Buffalo 1
Böblingen 1
Cairo 1
Canberra 1
Cinisello Balsamo 1
Cologne 1
Corsico 1
Dearborn 1
Esslingen am Neckar 1
Falkenstein 1
Hyderabad 1
Jinan 1
Krasnoyarsk 1
Kunming 1
Kuwait City 1
L'aquila 1
Lanzhou 1
Las Vegas 1
Magenta 1
Melbourne 1
Montreal 1
New Delhi 1
Palermo 1
Pune 1
Reggio Nell'emilia 1
San Francisco 1
Secaucus 1
São Paulo 1
Walnut 1
Warsaw 1
Totale 1.275
Salva come PNG Salva come JPEG
Nome #
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 75
Interaction between the cellular prion (PrPC) and the 2P domain K+ channel TREK-1 protein. 65
Postnatal development of Central Nervous System: anomalies in the formation of cerebellum fissures 64
The insect brain as a model to investigate the PCB effects. Changes of NOS-dependent NADPH diaphorase activity in Blattella germanica 61
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 60
Effects of cisplatin on neuronal cell B50: involvement of mitochondria in apoptosis induction. 59
Cell proliferation and death in the brain of active and hibernating frogs 58
Developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum 56
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 54
Interactions of neurotransmitter systems during postnatal development of the rat hippocampal formation: effects of cisplatin 45
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 45
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 45
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 44
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 40
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 39
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 38
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 38
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 38
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 38
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 38
Repurposing opportunities for Parkinson’s disease therapies 38
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 37
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 36
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 36
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 36
Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: Implications for reparative therapy in Parkinson's disease 35
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 35
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 34
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 33
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 33
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 32
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 32
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 30
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease 30
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 29
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 29
Mitochondrial Complex i Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease 26
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 23
Parkinson's Disease in Women and Men: What's the Difference? 22
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias 21
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells 20
Peripheral-central neuroimmune crosstalk in parkinson’s disease: What do patients and animal models tell us? 15
In vivo modeling of prodromal stage of Parkinson's disease 15
Role of autophagy in Parkinson’s disease 13
Parkinson’s disease 11
Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease 6
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? 3
Investigation and Comparison of Active and Passive Encapsulation Methods for Loading Proteins into Liposomes 3
Totale 1.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020169 38 54 0 6 0 10 3 8 1 15 34 0
2020/2021107 8 7 2 6 0 11 0 21 23 16 9 4
2021/2022189 0 1 3 0 1 5 2 11 10 0 33 123
2022/2023757 91 80 15 55 58 62 0 41 328 3 17 7
2023/2024362 54 50 14 15 27 96 20 22 6 14 28 16
2024/202535 35 0 0 0 0 0 0 0 0 0 0 0
Totale 1.713